Balyasny Asset Management
HUMA icon

Balyasny Asset Management’s Humacyte HUMA Stock Holding History

Balyasny Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,272
Closed -$122K – 2928
2022
Q1 		$122K Buy
+17,272
New +$101K ﹤0.01% 2112

Other funds holding HUMA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Balyasny Asset Management's HUMA Position: Q2 2022 in Review

Balyasny Asset Management sold out of Humacyte (HUMA) in Q2 2022, closing a stake of 17,272 shares — an estimated $122K sold.

Balyasny Asset Management first reported a position in HUMA in Q1 2022 and held it in 1 quarter. The position peaked at $122K in Q1 2022. 78 funds tracked by Wall St. Rank hold HUMA as of Q2 2022.

  • Balyasny Asset Management reported no remaining Humacyte position as of Q2 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 17,272 Humacyte shares in Q2 2022, an estimated $122K.
  • Balyasny Asset Management first reported a position in Humacyte in Q1 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Humacyte position peaked at $122K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Humacyte as of Q2 2022.

Based on Balyasny Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.